Clinical trials
Leukemia, Lymphocytic, Chronic, B-Cell clinical trials
Below are recruiting leukemia, lymphocytic, chronic, b-cell clinical trials, each written for real people, not researchers. We’re tracking 134 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06784167Recruiting
Vaccine response after CAR-T for myeloma and lymphoma
This study looks at how well vaccines work in people with multiple myeloma or certain lymphomas after they receive CAR-T cell therapy. It aims to help doctors understand the best way to revaccinate patients to protect against preventable diseases.
Portland, OregonAges 18 years+ - NCT06735664RecruitingPhase 1
Zanubrutinib and odronextamab for Richter's transformation
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06708897RecruitingPhase 1
Study of lonitoclax for returning B-cell blood cancers
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Louisville, KentuckyAges 18 years+ - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06693830Recruiting
Blood test guided treatment for newly diagnosed DLBCL
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
New York, New YorkAges 18 years+ - NCT05667506RecruitingPhase 1/Phase 2
Check CNCT19 cell therapy for relapsed childhood ALL
This early-stage trial tests a personalized immune-cell treatment called CNCT19 in children and teens whose leukemia (ALL) has come back or not responded to prior therapy. It may help the immune system recognize and attack leukemia cells that carry CD19.
Hefei, AnhuiAges 3–18 - NCT06644183RecruitingPhase 1/Phase 2
Triple therapy for relapsed CLL after prior treatments
This trial tests three drugs—roginolisib, venetoclax, and rituximab—for people with CLL that has come back or not responded after at least two prior treatments, including a BTK inhibitor. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT05607420RecruitingPhase 1/Phase 2
Testing a new cell therapy for relapsed lymphoma with CD20/CD22
This Phase 1/2 trial studies UCART20x22, a lab-made cell therapy, for people with certain types of relapsed or treatment-resistant B-cell non-Hodgkin lymphoma (NHL). It may help by targeting lymphoma cells that carry CD20 and/or CD22 markers and then testing safety and early effectiveness.
Chicago, IllinoisAges 18–80 - NCT06594939RecruitingPhase 2
Combination chemo for elderly DLBCL patients
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
Milwaukee, WisconsinAges 70 years+ - NCT06564038RecruitingPhase 1/Phase 2
Study of AZD0486 alone or with other drugs for B-cell cancers
This trial tests a new drug called AZD0486, alone or with other medicines, for people with certain types of B-cell cancers that have come back or not responded to treatment. The goal is to see how safe and effective it is.
Boston, MassachusettsAges 18 years+ - NCT06542250RecruitingPhase 1/Phase 2
Study of a new immune therapy for relapsed B-cell cancers
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
La Jolla, CaliforniaAges 18 years+ - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Duarte, CaliforniaAges 13–90 - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT06536452Recruiting
How blood cell production differs in CLL, MBL, and healthy people
This trial studies how the body makes blood cells in people with chronic lymphocytic leukemia (CLL), a related condition called monoclonal B-cell lymphocytosis (MBL), and in healthy volunteers matched by age. The goal is to understand differences that may help improve treatment or monitoring.
Rochester, MinnesotaAges 40 years+ - NCT06520098RecruitingPhase 2
BTK inhibitor with or without venetoclax for CLL/SLL
This trial tests whether adding venetoclax to your current BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib) works better than taking the BTK inhibitor alone. It's for veterans with CLL or SLL who have been on a BTK inhibitor for at least six months and have not had their disease get worse on that therapy.
San Francisco, CaliforniaAges 18–80 - NCT06514768RecruitingEarly Phase 1
JY231 injection for B-cell acute lymphoblastic leukemia
This trial tests a new injection (JY231) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has not responded well to treatment or has come back. It aims to see if the treatment can help reduce cancer cells in the bone marrow.
Kunming, YunnanAges Up to 75 years - NCT06528301RecruitingPhase 1
Trial of UB-VV111 with or without rapamycin for B-cell cancers
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06364423RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive leukemias and lymphomas
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
Bethesda, MarylandAges 18–120 - NCT06343311RecruitingPhase 1/Phase 2
T-cell therapy for adults with relapsed or refractory B-cell lymphoma
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Sacramento, CaliforniaAges 18 years+ - NCT06037018RecruitingPhase 1
Study of CC312 for B-cell blood cancers
This trial tests a new drug called CC312 for people with B-cell blood cancers that have come back or stopped responding to treatment. CC312 is designed to target CD19 on cancer cells, and the study checks if it is safe and how the body handles it.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06340737RecruitingPhase 1
CD22-targeting CAR T cells for relapsed B cell lymphoma
This trial tests whether giving modified immune cells (CAR T cells) that target CD22 on cancer cells can help people with certain B-cell lymphomas that have come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors or control the disease.
Palo Alto, CaliforniaAges 18 years+ - NCT06345027RecruitingPhase 1
CAR T cell therapy targeting CD70 for leukemia
This trial tests a new treatment made from your own immune cells, called CAR T cells, that are designed to find and attack leukemia cells with a specific marker called CD70. It may be an option if your leukemia has come back or not responded to standard treatments and you might be able to receive a stem cell transplant if this treatment helps.
Houston, TexasAges Up to 75 years - NCT06299540Recruiting
Physical activity program for CLL patients on ibrutinib
This study tests whether a personalized physical activity program can improve quality of life for people with CLL who are starting the drug ibrutinib. You would wear an activity watch and use a digital tool to track your activity over time.
ToulouseAges 18 years+ - NCT05705570RecruitingPhase 1
CAR-T for CD19-positive relapsed or resistant blood cancers
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
São Paulo, São PauloAges 2–70
Hear when a new Leukemia, Lymphocytic, Chronic, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia, lymphocytic, chronic, b-cell?
- Yes. Clin2 currently lists 134 recruiting leukemia, lymphocytic, chronic, b-cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia, lymphocytic, chronic, b-cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia, lymphocytic, chronic, b-cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.